CRIS Current Research Information System

GALIE', NAZZARENO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.388
AS - Asia 17.381
EU - Europa 12.030
SA - Sud America 1.267
AF - Africa 940
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 17
Totale 49.049
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.170
SG - Singapore 4.714
VN - Vietnam 4.593
CN - Cina 4.308
GB - Regno Unito 2.877
IT - Italia 2.361
DE - Germania 1.595
HK - Hong Kong 1.272
FR - Francia 915
BR - Brasile 895
SE - Svezia 806
IN - India 791
UA - Ucraina 705
RU - Federazione Russa 702
IE - Irlanda 496
NL - Olanda 405
KR - Corea 334
JP - Giappone 310
FI - Finlandia 284
ZA - Sudafrica 283
CI - Costa d'Avorio 251
EE - Estonia 200
AR - Argentina 154
CH - Svizzera 142
TG - Togo 134
JO - Giordania 129
CA - Canada 118
PH - Filippine 111
ID - Indonesia 107
BD - Bangladesh 104
AT - Austria 102
BG - Bulgaria 91
TH - Thailandia 91
SC - Seychelles 89
TR - Turchia 89
IQ - Iraq 84
PK - Pakistan 62
PL - Polonia 62
MX - Messico 60
EC - Ecuador 58
TW - Taiwan 50
CO - Colombia 49
BE - Belgio 44
ES - Italia 44
SA - Arabia Saudita 41
NG - Nigeria 38
CL - Cile 33
GR - Grecia 32
EG - Egitto 29
UZ - Uzbekistan 29
IR - Iran 28
AU - Australia 22
LT - Lituania 22
PY - Paraguay 22
VE - Venezuela 22
HU - Ungheria 20
MY - Malesia 19
RO - Romania 19
PE - Perù 18
HR - Croazia 17
MA - Marocco 17
KE - Kenya 16
DZ - Algeria 15
LB - Libano 15
CZ - Repubblica Ceca 14
AL - Albania 13
AZ - Azerbaigian 13
NE - Niger 13
UY - Uruguay 13
AE - Emirati Arabi Uniti 12
KZ - Kazakistan 12
ET - Etiopia 11
DK - Danimarca 10
OM - Oman 10
DO - Repubblica Dominicana 9
PS - Palestinian Territory 9
TN - Tunisia 9
XK - ???statistics.table.value.countryCode.XK??? 9
SK - Slovacchia (Repubblica Slovacca) 8
SY - Repubblica araba siriana 8
IL - Israele 7
JM - Giamaica 7
PT - Portogallo 7
RS - Serbia 7
HN - Honduras 6
SN - Senegal 6
GH - Ghana 5
NP - Nepal 5
A2 - ???statistics.table.value.countryCode.A2??? 4
CR - Costa Rica 4
EU - Europa 4
GE - Georgia 4
LU - Lussemburgo 4
LV - Lettonia 4
MK - Macedonia 4
NZ - Nuova Zelanda 4
BO - Bolivia 3
BY - Bielorussia 3
GT - Guatemala 3
KW - Kuwait 3
Totale 48.982
Salva come PNG Salva come JPEG
Città #
Singapore 3.238
Southend 2.445
Ashburn 1.785
Fairfield 1.759
Hong Kong 1.224
Ho Chi Minh City 1.063
Chandler 1.058
Hanoi 929
San Jose 928
Woodbridge 882
Wilmington 807
Seattle 744
Houston 733
Hefei 715
Dong Ket 674
Princeton 648
Beijing 647
Santa Clara 643
Cambridge 593
Dublin 491
Boardman 451
Jacksonville 437
Ann Arbor 421
Lauterbourg 393
Bologna 352
Seoul 279
Tokyo 271
Westminster 261
Los Angeles 258
Abidjan 251
Padova 249
Nanjing 242
Milan 205
Berlin 190
New York 185
Helsinki 171
Buffalo 170
Jinan 148
Council Bluffs 147
Turin 142
Haiphong 141
The Dalles 140
Lomé 133
Da Nang 130
Saint Petersburg 127
Shenyang 125
Amman 124
Redondo Beach 120
San Diego 120
Dallas 112
Frankfurt am Main 112
Bern 110
Guangzhou 100
Mülheim 95
São Paulo 95
Rome 92
Changsha 91
Sofia 88
Hebei 84
Bengaluru 82
Medford 79
Munich 78
Shanghai 78
Tianjin 73
Nuremberg 72
Des Moines 68
Nanchang 66
London 65
Lappeenranta 62
Chicago 61
Hangzhou 61
Jiaxing 58
Zhengzhou 58
Vienna 56
Johannesburg 54
Turku 51
Mahé 48
Phoenix 48
Redmond 48
Biên Hòa 47
Jakarta 47
Florence 46
Warsaw 46
Can Tho 45
Yubileyny 45
Dearborn 44
Enfield 44
Shenzhen 44
Olalla 43
Bangkok 42
Brussels 42
Hải Dương 42
Amsterdam 41
Falls Church 41
Toronto 41
Bremen 40
Falkenstein 38
Thái Nguyên 37
Baghdad 36
Abeokuta 35
Totale 31.520
Salva come PNG Salva come JPEG
Nome #
Impact of admission hyperglycemia on short and long-term prognosis in acute myocardial infarction: MINOCA versus MIOCA 435
Prolasso valvolare mitralico e disgiunzione mitro-anulare. La consapevolezza di un possibile substrato aritmico 345
Female gender and mortality in ST-segment-elevation myocardial infarction treated with primary PCI 276
[Pulmonary hypertension in chronic lung diseases] 271
Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells 269
L’angioplastica delle arterie polmonari nel cuore polmonare cronico tromboembolico: 5 anni di esperienza in Italia 262
A new CT-score as index of hemodynamic changes in patients with chronic thromboembolic pulmonary hypertension 260
Is Pulmonary Artery Pulsatility Index (PAPi) a Predictor of Outcome after Pulmonary Endarterectomy? 256
Complicanze del cateterismo cardiaco destro in pazienti con ipertensione polmonare precapillare di grado severo. 251
A Combined Targeted and Whole Exome Sequencing Approach Identified Novel Candidate Genes Involved in Heritable Pulmonary Arterial Hypertension 242
Sex-Related Disparities in Cardiac Masses: Clinical Features and Outcomes 241
Lung neovascularity in pulmonary arterial hypertension associated with congenital heart defects and idiopathic pulmonary arterial hypertension: study of 198 patients 240
2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. 239
Angioplastica delle arterie polmonari nel cuore polmonare cronico tromboembolico: un caso clinico paradigmatico 230
Il test acuto di vasoreattività nei pazienti con ipertensione arteriosa polmonare. 229
Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: Real-world insights 229
Diagnostic Accuracy of Cardiac Computed Tomography and 18F-Fluorodeoxyglucose With Positron Emission Tomography in Cardiac Masses 228
Evaluation of mosaic pattern areas in HRCT with Min-IP reconstructions in patients with pulmonary hypertension: could this evaluation replace lung perfusion scintigraphy? 226
Pulmonary Arterial Hypertension associated to connective tissue diseases 221
Effetti emodinamici e funzionali dell'epoprostenolo in associazione agli antagonisti recettoriali dell'endotelina e agli inibitori delle fosfodiesterasi-5 220
Application of a new pulmonary artery obstruction score in the prognostic evaluation of acute pulmonary embolism: comparison with clinical and haemodynamic parameters [Applicazione di un nuovo score di ostruzione vascolare nella valutazione prognostica dell'embolia polmonare acuta. Confronto con i parametri clinico-emodinamici] 217
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry 215
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension 209
Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes 204
Aiming at the appropriate target for the treatment of pulmonary hypertension due to left heart disease 200
In vitro thrombogenicity of drug-eluting and bare metal stents 200
Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people 199
Regressione delle alterazioni elettrocardiografiche indicative di ipertrofia ventricolare destra nei pazienti con ipertensione arteriosa polmonare. 198
Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study 196
Use of Diltiazem in Chronic Rate Control for Atrial Fibrillation: A Prospective Case-Control Study 195
BMPR2 mutations and survival in pulmonary arterial hypertension: An individual participant data meta-analysis 193
Dissecting histone deacetylase role in pulmonary arterial smooth muscle cell proliferation and migration 193
Electrocardiogram analysis in Anderson-Fabry disease: a valuable tool for progressive phenotypic expression tracking 189
Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. 188
Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. 187
Andamento clinico, emodinamico e dei livelli plasmatici dell’NT-pro BNP in pazienti con ipertensione polmonare precapillare 187
Secondary prevention medical therapy and outcomes in patients with myocardial infarction with non-obstructive coronary artery disease 185
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension 184
Development and Validation of a Diagnostic Echocardiographic Mass Score in the Approach to Cardiac Masses 183
Circulating miR-184 is a potential predictive biomarker of cardiac damage in Anderson–Fabry disease 183
Occurring of In Vitro Functional Vasculogenic Pericytes from Human Circulating Early Endothelial Precursor Cell Culture 182
Therapeutic alternatives in chronic thromboembolic pulmonary hypertension: from pulmonary endarterectomy to balloon pulmonary angioplasty to medical therapy. State of the art from a multidisciplinary team 182
Correlations Between Cardiac Magnetic Resonance and Myocardial Histologic Findings in Fabry Disease 181
Ambrisentan therapy for pulmonary arterial hypertension. 181
[Pulmonary hypertension due to left heart diseases] 181
Sodium butyrate inhibits platelet-derived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through Akt inhibition. 180
Densitometric CT evaluation of acute and chronic thromboembolic filling defects of the pulmonary arteries before and after contrast injection = Valutazione densitometrica dei difetti di riempimento tromboembolici acuti e cronici delle arterie polmonari prima e dopo somministrazione di mezzo di contrasto 179
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension 178
Anticoagulant treatment in patients with pulmonary arterial hypertension associated with systemic sclerosis: More shadows than lights 177
A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines 177
Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA 175
Current therapeutic approaches to pulmonary arterial hypertension. 174
Effetti del trattamento con sildenafil nei pazienti con ipertensione arteriosa polmonare idiopatica, associata e cuore polmonare cronico tromboembolico. 173
Preoperative checklist to reduce the risk of cardiac implantable electronic device infections 173
Genetics and clinical phenotype of Erdheim–Chester disease: A case report of constrictive pericarditis and a systematic review of the literature 172
The endothelin system in pulmonary arterial hypertension. 172
New insights on pulmonary arterial hypertension. 171
Significato prognostico dell'aerea del rigurgito tricuspidalico nei pazienti con ipertensione arteriosa polmonare idiopatica trattati secondo le attuali linee guida. 171
Genere femminile e ipertensione arteriosa polmonare: una relazione complessa Female gender and pulmonary arterial hypertension: a complex relationship 170
Effetti clinici ed emodinamici del trattamento con sildenafil nei pazienti con ipertensione arteriosa polmonare. 169
Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension. 168
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. 168
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS 168
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. 166
Pulmonary endarterectomy: is there an alternative to profound hypothermia with cardiocirculatory arrest? 166
BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. 166
Bronchial artery embolization for the treatment of haemoptysis in pulmonary hypertension 166
Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension and Angina 166
Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. 165
Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study 165
Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients 165
Sildenafil therapy in patients with porto-pulmonary hypertension 163
Clinical classification of pulmonary hypertension. 162
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism 162
Clinical presentations leading to arrhythmogenic left ventricular cardiomyopathy 160
Pulmonary endarterectomy: an alternative to circulatory arrest and deep hypothermia: mid-term results 160
Confronto tra antagonista recettoriali selettivi e non selettivi dell'endotelina nel trattamento dell'ipertensione arteriosa polmonare. 159
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. 158
Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients 158
Pulmonary Arterial Hypertension Associated with Portal Hypertension and HIV Infection: Comparative Characteristics and Prognostic Predictors 157
The role of physical activity in individuals with cardiovascular risk factors: An opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport 157
Primary malignant pericardial tumour in Lynch syndrome 157
Cardiologia pediatrica. Problematiche cliniche 157
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. 156
Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis. 156
Pulmonary hypertension in primary Sjogren's syndrome: report of a case and review of the literature. 155
Pulmonary arterial hypertension. Part II: Medical and surgical treatment 155
Rare causes of pulmonary hypertension. Spectrum of radiological findings and review of the literature 155
Coronary Protection to Prevent Coronary Obstruction During Transcatheter Aortic Valve Replacement: A Multicenter International Registry 155
Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study 154
Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. 153
Effetti del sildenafil in soggetti con cuore polmonare cronico tromboembolico 153
2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension 153
Prognostic value of high-sensitivity cardiac troponin I early after coronary artery bypass graft surgery 152
Impact of Elective, Uncomplicated Target Lesion Revascularization on Cardiac Mortality After Elective Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery Disease 152
Pulmonary arterial hypertension: a look to the future. 151
Pulmonary veno-occlusive disease: the role of CT 150
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. 149
Reply to SGLT-2 inhibitors: Post-infarction interventional effects 147
Management of Pulmonary Arterial Hypertension Associated with Congenital Systemic-to-Pulmonary Shunts and Eisenmenger's Syndrome. 147
Totale 18.925
Salva come PNG Salva come JPEG
Categoria #
all - tutte 142.781
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 142.781
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.381 0 0 0 0 0 0 0 0 0 183 172 1.026
2021/20225.006 479 181 333 320 432 272 125 416 183 265 1.081 919
2022/20235.513 547 692 264 659 293 395 205 274 1.000 236 562 386
2023/20241.791 135 256 107 148 163 262 103 134 79 189 95 120
2024/20257.514 322 1.262 794 504 1.035 469 493 248 173 474 382 1.358
2025/202616.963 1.487 1.747 1.729 1.450 2.085 1.003 1.891 689 3.757 1.125 0 0
Totale 49.988